Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis?
- PMID: 32271624
- DOI: 10.1161/CIRCULATIONAHA.120.047419
Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis?
Keywords: COVID-19; atypical hemolytic-uremic syndrome; complement; immunosuppressive agents; thrombotic microangiopathies.
Comment on
-
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950. JAMA Cardiol. 2020. PMID: 32211816 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical